

Market Announcement

2 November 2020

MedAdvisor Limited (ASX: MDR) – Trading Halt (2+2)

Description

The securities of MedAdvisor Limited ('MDR') will be placed in trading halt at MDR's request, pending it releasing an announcement about the outcome of the institutional component of the accelerated entitlement offer. Unless ASX decides otherwise, the securities will remain in trading halt until the commencement of normal trading on Friday, 6 November 2020.

Issued by

Sandra Wutete

Senior Adviser, Listings Compliance (Perth)



MedAdvisor Limited

ACN 145 327 617
Level 2
971 Burke Road
Camberwell VIC 3124

phone +61 3 9095 3036
fax: +61 3 9428 4664
email: corporate@medadvisor.com.au
PO Box 8225 Camberwell North VIC 3124

2 November 2020

Mr Sean Maloney
Listings Compliance (Perth)
ASX Limited
Level 40, Central Park
152-158 St George's Terrace
Perth WA 6000

Dear Sir

MedAdvisor Limited (ASX:MDR) - Request for Trading Halt and Voluntary Suspension

Pursuant to ASX Listing Rules 17.1 and 17.2, MedAdvisor Limited ACN 145 327 617 (**Company**) requests that the ASX grants a trading halt and voluntary suspension with respect to the Company's shares.


The Company provides the following information regarding this request:

1. The reason for the trading halt and voluntary suspension is that the Company intends to make an announcement regarding a material acquisition and a capital raising to be undertaken by way of an accelerated, pro rata non-renounceable entitlement offer accompanied by an institutional placement (together, the **Offer**). The trading halt and voluntary suspension are required to enable the institutional component of the Offer to be conducted in an orderly manner on ASX.
2. The Company requests that the trading halt continues until the earliest of:
 - (a) such time as the Company makes an announcement to the market in relation to the outcome of the institutional component of the Offer;
 - (b) the open of trading on Friday, 6 November 2020; and
 - (c) the Company separately requests that the trading halt be lifted.
3. In the event that the Company has not made an announcement to the market in relation to the outcome of the institutional component of the Offer before the open of trading on Friday, 6 November 2020 or has not separately requested that the trading halt be lifted, the Company requests that a voluntary suspension of the Company's securities from the commencement of trading on Friday, 6 November 2020 until the earliest of:
 - (a) such time as the Company makes an announcement to the market in relation to the outcome of the institutional component of the Offer;
 - (b) the open of trading on Tuesday, 11 November 2020; and
 - (c) the Company separately requests that the voluntary suspension be lifted.
4. The Company expects that the ASX announcement about the acquisition and the Offer will be made before 12.00pm today and a further announcement about the

outcome of the institutional component of the Offer as soon as possible, and in any event, prior to the open of trading on Tuesday, 11 November 2020.

5. The Company considers that the trading halt and voluntary suspension are necessary as otherwise trading in the Company's shares would continue on an uninformed basis.
6. The Company is not aware of any reason why a trading halt or voluntary suspension should not be granted or any other information necessary to inform the market about the requested trading halt or voluntary suspension.

Yours sincerely



Naomi Lawrie
Company Secretary
MedAdvisor Limited